MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, has announced positive results from its Phase 2 THIO-101 clinical trial. The trial evaluated the efficacy of their lead clinical candidate, ateganosine (THIO), in combination with Regeneron's immune checkpoint inhibitor cemiplimab (Libtayo®) for patients with advanced non-small cell lung cancer (NSCLC) resistant to prior therapies. The latest data reveals a median overall survival $(OS)$ of 17.8 months for patients receiving at least one dose of ateganosine, significantly outperforming the typical 5 to 6 months OS seen in standard-of-care chemotherapy for similar cases. These findings suggest that ateganosine may considerably impact the NSCLC treatment landscape, with potential for accelerated FDA approval and exclusivity. The treatment has been generally well-tolerated in this heavily pre-treated patient population.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.